Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022)

Edgewise Therapeutics has reported Total Non-Current Liabilities over the past 2 years, most recently at $10.9 million for Q2 2022.

  • Quarterly results put Total Non-Current Liabilities at $10.9 million for Q2 2022, changed N/A from a year ago — trailing twelve months through Jun 2022 was $10.9 million (changed N/A YoY), and the annual figure for FY2021 was $10.5 million, changed.
  • Total Non-Current Liabilities reached $10.9 million in Q2 2022 per EWTX's latest filing, down from $12.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $12.2 million in Q1 2022 and bottomed at $8.8 million in Q3 2021.